The new radioactive imaging agent has been bought from its developer, Germany’s Bayer AG by Indian drugmaker Piramal Healthcare.
Now in late clinical trials and likely to be approved by federal drug regulators late this year, florbetaben — an experimental radioactive agent — is expected to help doctors make an early diagnosis of Alzheimer’s disease in people suffering the serious memory and cognitive problems of dementia.
That’s good news for millions of people worldwide who are at risk of developing the feared mind-robbing disease. An early way to detect the disease will help scientists find a cure for Alzheimer’s, which has been elusive so far. Medical experts believe that the drugs being investigated in clinical trials to treat this neurodegenerative disease have failed mainly because the patients enrolled in such trials are suffering late-stage Alzheimer’s that’s progressed too far for the drugs to be effective.